Core Insights - Aardvark Therapeutics, Inc. is advancing its clinical pipeline with significant progress in its lead compounds ARD-101 and ARD-201, targeting metabolic diseases and obesity [2][4][7] Clinical Program Updates - The Phase 3 HERO trial for ARD-101 will expand to include patients under 13 years old, aiming to address hyperphagia associated with Prader-Willi Syndrome (PWS) [3][7] - ARD-201, an oral obesity therapy, has shown promising preclinical results in reducing body weight and preventing weight regain after discontinuation of GLP-1 receptor agonist therapy, leading to its advancement in two Phase 2 trials: POWER and STRENGTH [4][7] Business Highlights - Aardvark has strengthened its leadership team with key appointments in scientific, commercial, regulatory, and legal roles, enhancing its operational capabilities [6] - The company reported a cash position of $141.8 million as of June 30, 2025, which is expected to support operations into 2027 [7][13] Financial Performance - For the second quarter of 2025, Aardvark reported research and development expenses of $13.1 million, a significant increase from $4.0 million in the same quarter of 2024, primarily due to higher development costs for ARD-101 [13] - The net loss for the quarter was $14.4 million, compared to a net loss of $5.4 million in the prior year, reflecting increased operational expenses [13][16]